Zinc phthalocyanine conjugated with the amino-terminal fragment of urokinase for tumor-targeting photodynamic therapy

Acta Biomaterialia

Volumn 10, Issue 10, 2014, Pages 4257-4268

  Chen, Zhuo ^a   Xu, Peng ^a   Chen, Jincan ^a   Chen, Hongwei ^a   Hu, Ping ^a   Chen, Xueyuan ^b   Lin, Lin ^c   Huang, Yunmei ^d   Zheng, Ke ^e   Zhou, Shanyong ^a   Li, Rui ^a   Chen, Song ^a   Liu, Jianyong ^e   Xue, Jinping ^e   Huang, Mingdong ^a,e  

^a FUJIAN INSTITUTE OF RESEARCH ON THE STRUCTURE OF MATTER   (China)

^b FUJIAN INSTITUTE OF RESEARCH ON THE STRUCTURE OF MATTER   (China)

^c HARVARD MEDICAL SCHOOL   (United States)

^d FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^e FUZHOU UNIVERSITY   (China)

Author keywords

Photosensitizer; Tumor imaging; Tumor targeting; Zinc phthalocyanine

Indexed keywords

CHEMOTHERAPY; DISEASES; MICROCOMPUTERS; PHOTOSENSITIZERS; TUMORS; ZINC; ZINC COMPOUNDS;

HIGH SPECIFICITY; MULTIDRUG RESISTANCE; PHOTOCHEMICAL PROPERTIES; PHOTOPHYSICAL PROPERTIES; PHOTOSENSITISER; SIMPLE++; SYSTEMIC TOXICITIES; TUMOR IMAGING; TUMOR-TARGETING; ZINC PHTHALOCYANINES;

PHOTODYNAMIC THERAPY;

PHTHALOCYANINE ZINC; UROKINASE; INDOLE DERIVATIVE; PHTHALOCYANINE; TUMOR MARKER; TUMOR PROTEIN; UROKINASE RECEPTOR; ZINC;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; AGONISTS; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG SCREENING; METABOLISM; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PHOTOCHEMOTHERAPY; PROCEDURES; U937 CELL LINE;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; INDOLES; MICE; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; PHOTOCHEMOTHERAPY; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; TUMOR MARKERS, BIOLOGICAL; U937 CELLS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZINC;

EID: 84908230369     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2014.06.026     Document Type: Article

References (60)

1. C.A. Robertson, D.H. Evans, and H. Abrahamse Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT J Photochem Photobiol B 96 2009 1 8
2. A.D. Garg, D. Nowis, J. Golab, and P. Agostinis Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity Apoptosis 15 2010 1050 1071
3. R. Hudson, and R.W. Boyle Strategies for selective delivery of photodynamic sensitisers to biological targets J Porphyrins Phthalocyanines 8 2004 954 975
4. A. Wang, L. Long, and C. Zhang Synthesis and properties of photo-activable phthalocyanines: a brief overview J Inclusion Phenom Macrocyclic Chem 71 2011 1 24
5. M. Triesscheijn, P. Baas, J.H. Schellens, and F.A. Stewart Photodynamic therapy in oncology Oncologist 11 2006 1034 1044
6. J.P. Taquet, C. Frochot, V. Manneville, and M. Barberi-Heyob Phthalocyanines covalently bound to biomolecules for a targeted photodynamic therapy Curr Med Chem 14 2007 1673 1687
7. S.-i. Ogura, K. Tabata, K. Fukushima, T. Kamachia, and I. Okur Development of phthalocyanines for photodynamic therapy J Porphyrins Phthalocyanines 10 2006 1116 1124
8. L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, and S. Taube American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 2007 5287 5312
9. N. Harbeck, R.E. Kates, K. Gauger, A. Willems, M. Kiechle, and V. Magdolen Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer Thromb Haemost 91 2004 450 456
10. Q. Huai, A.P. Mazar, A. Kuo, G.C. Parry, D.E. Shaw, and J. Callahan Structure of human urokinase plasminogen activator in complex with its receptor Science 311 2006 656 659
11. L. Lin, H. Gardsvoll, Q. Huai, M. Huang, and M. Ploug Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy J Biol Chem 285 2010 10982 10992
12. M.P. Stoppelli, A. Corti, A. Soffientini, G. Cassani, F. Blasi, and R.K. Assoian Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes Proc Natl Acad Sci USA 82 1985 4939 4943
13. C. Barinka, G. Parry, J. Callahan, D.E. Shaw, A. Kuo, and K. Bdeir Structural basis of interaction between urokinase-type plasminogen activator and its receptor J Mol Biol 363 2006 482 495
14. P. Llinas, M.H. Le Du, H. Gardsvoll, K. Danø, M. Ploug, and B. Gilquin Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide EMBO J 24 2005 1655 1663
15. K. Dass, A. Ahmad, A.S. Azmi, S.H. Sarkar, and F.H. Sarkar Evolving role of uPA/uPAR system in human cancers Cancer Treat Rev 34 2008 122 136
16. B.S. Nielsen, F. Rank, M. Illemann, L.R. Lund, and K. Dano Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor Int J Cancer 120 2007 2086 2095
17. R.W. Stephens, H.J. Nielsen, I.J. Christensen, O. Thorlacius-Ussing, S. Sorensen, and K. Dano Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis J Natl Cancer Inst 91 1999 869 874
18. M. Persson, and A. Kjaer Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications Clin Physiol Funct Imaging 33 2013 329 337
19. M.O. Abdalla, P. Karna, H.K. Sajja, H. Mao, C. Yates, and T. Turner Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy J Control Release 149 2011 314 322
20. L. Yang, H. Mao, Z. Cao, Y.A. Wang, X. Peng, and X. Wang Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles Gastroenterology 136 1514-25 2009 e2
21. M. Persson, M. Hosseini, J. Madsen, T.J. Jorgensen, K.J. Jensen, and A. Kjaer Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies Theranostics 3 2013 618 632
22. L. Yang, X.H. Peng, Y.A. Wang, X. Wang, Z. Cao, and C. Ni Receptor-targeted nanoparticles for in vivo imaging of breast cancer Clin Cancer Res 15 2009 4722 4732
23. M. De Souza, H. Matthews, J.A. Lee, M. Ranson, and M.J. Kelso Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand Bioorg Med Chem 19 2011 2549 2556
24. S.A. Rabbani, A.P. Mazar, S.M. Bernier, M. Haq, I. Bolivar, and J. Henkin Structural requirements for the growth factor activity of the amino-terminal domain of urokinase J Biol Chem 267 1992 14151 14156
25. M. da Volta Soares, M.R. Oliveira, E.P. Dos Santos, L. de Brito Gitirana, G.M. Barbosa, and C.H. Quaresma Nanostructured delivery system for zinc phthalocyanine: preparation, characterization, and phototoxicity study against human lung adenocarcinoma A549 cells Int J Nanomed 6 2011 227 238
26. W.S. Kuo, Y.T. Chang, K.C. Cho, K.C. Chiu, C.H. Lien, and C.S. Yeh Gold nanomaterials conjugated with indocyanine green for dual-modality photodynamic and photothermal therapy Biomaterials 33 2012 3270 3278
27. F. Dumoulin, M. Durmuş, V. Ahsen, and T. Nyokong Synthetic pathways to water-soluble phthalocyanines and close analogs Coord Chem Rev 254 2010 2792 2847
28. G. Zhao, C. Yuan, C. Bian, X. Hou, X. Shi, and X. Ye Protein expression and preliminary crystallographic analysis of amino-terminal fragment of urokinase-type plasminogen activator Protein Expr Purif 49 2006 71 77
29. J. Chen, N. Chen, J. Huang, J. Wang, and M. Huang Derivatizable phthalocyanine with single carboxyl group: synthesis and purification Inorg Chem Commun 9 2006 313 315
30. Z. Chen, S. Zhou, J. Chen, Y. Deng, Z. Luo, and H. Chen Pentalysine beta-carbonylphthalocyanine zinc: an effective tumor-targeting photosensitizer for photodynamic therapy ChemMedChem 5 2010 890 898
31. N.A. Kuznetsova, N.S. Gretsova, E.A. Kalmykova, E.A. Makarova, S.N. Dashkevich, and V.M. Negrimovskii Relationship between the photochemical properties and structure of porphyrins and related compounds Russ J Gen Chem 70 2000 133 140
32. L. Li, Z. Luo, Z. Chen, J. Chen, S. Zhou, and P. Xu Enhanced photodynamic efficacy of zinc phthalocyanine by conjugating to heptalysine Bioconjug Chem 23 2012 2168 2172
33. P. Xu, J. Chen, Z. Chen, S. Zhou, P. Hu, and X. Chen Receptor-targeting phthalocyanine photosensitizer for improving antitumor photocytotoxicity PLoS One 7 2012 e37051
34. D. Schaudien, S. Schwab, S. Linke, F. Seeliger, G. Pauli, and W. Baumgartner Lack of detectable West Nile virus RNA in brains and kidneys of dogs and cats with immunohistological precipitates using virus-specific antibodies Vet Microbiol 132 2008 171 176
35. M. Ploug, and V. Ellis Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins FEBS Lett 349 1994 163 168
36. R. Picone, E.L. Kajtaniak, L.S. Nielsen, N. Behrendt, M.R. Mastronicola, and M.V. Cubellis Regulation of urokinase receptors in monocyte like U937 cells by phorbol ester phorbol myristate acetate J Cell Biol 108 1989 693 702
37. M. Ploug, E. Ronne, N. Behrendt, A.L. Jensen, F. Blasi, and K. Dano Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol J Biol Chem 266 1991 1926 1933
38. S. Shetty, T. Velusamy, S. Idell, P. Shetty, A.P. Mazar, and Y.P. Bhandary Regulation of urokinase receptor expression by p53: novel role in stabilization of uPAR mRNA Mol Cell Biol 27 2007 5607 5618
39. R.J. Abi-Habib, R. Singh, S.H. Liu, T.H. Bugge, S.H. Leppla, and A.E. Frankel A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types Mol Cancer Ther 5 2006 2556 2562
40. S.D. Conner, and S.L. Schmid Regulated portals of entry into the cell Nature 422 2003 37 44
41. Y. Zorlu, M.A. Ermeydan, F. Dumoulin, V. Ahsen, H. Savoie, and R.W. Boyle Glycerol and galactose substituted zinc phthalocyanines. Synthesis and photodynamic activity Photochem Photobiol Sci 8 2009 312 318
42. F. Blasi, and P. Carmeliet UPAR: a versatile signalling orchestrator Nat Rev Mol Cell Biol 3 2002 932 943
43. A. Nykjaer, M. Conese, E.I. Christensen, D. Olson, O. Cremona, and J. Gliemann Recycling of the urokinase receptor upon internalization of the uPA: serpin complexes EMBO J 16 1997 2610 2620
44. C. Fabris, G. Valduga, G. Miotto, L. Borsetto, G. Jori, and S. Garbisa Photosensitization with zinc (II) phthalocyanine as a switch in the decision between apoptosis and necrosis Cancer Res 61 2001 7495 7500
45. E. Alexandratou, D. Yova, and S. Loukas A confocal microscopy study of the very early cellular response to oxidative stress induced by zinc phthalocyanine sensitization Free Radic Biol Med 39 2005 1119 1127
46. A.P. Castano, P. Mroz, and M.R. Hamblin Photodynamic therapy and anti-tumour immunity Nat Rev Cancer 6 2006 535 545
47. P. Mroz, J.T. Hashmi, Y.Y. Huang, N. Lange, and M.R. Hamblin Stimulation of anti-tumor immunity by photodynamic therapy Expert Rev Clin Immunol 7 2011 75 91
48. B.W. Henderson, S.M. Waldow, T.S. Mang, W.R. Potter, P.B. Malone, and T.J. Dougherty Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy Cancer Res 45 1985 572 576
49. E.D. Baron, C.L. Malbasa, D. Santo-Domingo, P. Fu, J.D. Miller, and K.K. Hanneman Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial Lasers Surg Med 42 2010 728 735
50. M.J. Egorin, E.G. Zuhowski, D.L. Sentz, J.M. Dobson, P.S. Callery, and J.L. Eiseman Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent Cancer Chemother Pharmacol 44 1999 283 294
51. M. Lam, A.H. Hsia, Y. Liu, M. Guo, A.R. Swick, and J.C. Berlin Successful cutaneous delivery of the photosensitizer silicon phthalocyanine 4 for photodynamic therapy Clin Exp Dermatol 36 2011 645 651
52. W.G. Love, S. Duk, R. Biolo, G. Jori, and P.W. Taylor Liposome-mediated delivery of photosensitizers: localization of zinc (II)-phthalocyanine within implanted tumors after intravenous administration Photochem Photobiol 63 1996 656 661
53. L.B. Josefsen, and R.W. Boyle Photodynamic therapy and the development of metal-based photosensitisers Met Based Drugs 2008 2008 276109
54. J. Shao, J. Xue, Y. Dai, H. Liu, N. Chen, and L. Jia Inhibition of human hepatocellular carcinoma HepG2 by phthalocyanine photosensitiser PHOTOCYANINE: ROS production, apoptosis, cell cycle arrest Eur J Cancer 48 2012 2086 2096
55. J. Xue, C. Li, H. Liu, J. Wei, N. Chen, and J. Huang Optimal light dose and drug dosage in the photodynamic treatment using PHOTOCYANINE Photodiagn Photodyn Ther 8 2011 267 274
56. B. Yang, H. Yao, H. Liu, Z. Jiang, J. Wang, and W. He Structural identification and quality study on isomers of a novel anticancer photosensitiser photocyanine Yao Xue Xue Bao 45 2010 1545 1549
57. J.P. Celli, B.Q. Spring, I. Rizvi, C.L. Evans, K.S. Samkoe, and S. Verma Imaging and photodynamic therapy: mechanisms, monitoring, and optimization Chem Rev 110 2010 2795 2838
58. D. Cantero, H. Friess, J. Deflorin, A. Zimmermann, M.A. Brundler, and E. Riesle Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma Br J Cancer 75 1997 388 395
59. H. Pedersen, N. Brunner, D. Francis, K. Osterlind, E. Ronne, and H.H. Hansen Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue Cancer Res 54 1994 4671 4675
60. M. Yamamoto, R. Sawaya, S. Mohanam, V.H. Rao, J.M. Bruner, and G.L. Nicolson Expression and localization of urokinase-type plasminogen activator receptor in human gliomas Cancer Res 54 1994 5016 5020